panCELLa, Implant Therapeutics, and Pluristyx Announce Definitive Merger Agreement.
Read the Press Release
Read the FAQ
panCELLa provides stem cells as a source for “FailSafe® off-the-shelf cell therapy” targeting degenerative, infectious and malignant diseases
panCELLa granted patent in the United Kingdom for induced Allogeneic Cell Tolerance (iACT Stealth™) Technology January 12, 2023 – Toronto – Pluristyx and panCELLa today are excited to announce the granting of a pa...
Fully integrated companies streamline access to genetically modified stem cells for clinical development October 6, 2022 – Seattle, Washington - Today, Pluristyx, panCELLa, and Implant Therapeutics management...
panCELLa is honoured to be recognized by Life Sciences Review and one of the Top 10 Biotech Companies in Canada. https://www.lifesciencesreview.com/pancella...